Search

Your search keyword '"Tassi, V"' showing total 237 results
Start Over Author "Tassi, V"
237 results on '"Tassi, V"'

1. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Author

Cantini, L., Mentrasti, G., Russo, G.L., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., Verde, N. La, Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E.G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D’Emilio, V., Cona, M.S., Guida, A., Caglio, A., Salerno, F., Spinelli, G., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M. L. Bruno, and Berardi, R.

Published
2022
Full Text
View/download PDF

2. OC-0763 SAbR in LA-NSCLC patients unfit for concurrent ChT-RT: START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., primary, Anselmo, P., additional, Casale, M., additional, Zannori, C., additional, Loreti, F., additional, Ragusa, M., additional, Enrico, B., additional, Mancioli, F., additional, Marchetti, G., additional, Italiani, M., additional, Fabiani, S., additional, Guida, A., additional, Tassi, V., additional, Caprera, C., additional, Corsi, M., additional, Bracarda, S., additional, Maranzano, E., additional, and Trippa, F., additional

Published
2023
Full Text
View/download PDF

3. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406](S2059702922000278)(10.1016/j.esmoop.2022.100406)

Author

Cantini L., Mentrasti G., Lo Russo G., Signorelli D., Pasello G., Rijavec E., Russano M., Antonuzzo L., Rocco D., Giusti R., Adamo V., Genova C., Tuzi A., Morabito A., Gori S., La Verde N., Chiari R., Cortellini A., Cognigni V., Pecci F., Indini A., De Toma A., Zattarin E., Oresti S., Pizzutilo E. G., Frega S., Erbetta E., Galletti A., Citarella F., Fancelli S., Caliman E., Della Gravara L., Malapelle U., Filetti M., Piras M., Toscano G., Zullo L., De Tursi M., Di Marino P., D'Emilio V., Cona M. S., Guida A., Caglio A., Salerno F., Spinelli G. P., Bennati C., Morgillo F., Russo A., Dellepiane C., Vallini I., Sforza V., Inno A., Rastelli F., Tassi V., Nicolardi L., Pensieri M. V., Emili R., Roca E., Migliore A., Galassi T., Rocchi M. B. L., Berardi R., Cantini, L., Mentrasti, G., Lo Russo, G., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., La Verde, N., Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E. G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D'Emilio, V., Cona, M. S., Guida, A., Caglio, A., Salerno, F., Spinelli, G. P., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, M. V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M. B. L., and Berardi, R.

Abstract

The publisher regrets that at the time the article was published the name of the author N. La Verde was mistakenly abbreviated as N.L. Verde. This has now been corrected. The publisher would like to apologise for any inconvenience caused.

Published
2022

4. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]

Author

Cantini, L., Mentrasti, G., Lo Russo, G., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., La Verde, N., Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E.G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D’Emilio, V., Cona, M.S., Guida, A., Caglio, A., Salerno, F., Spinelli, G.P., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, M.V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M.B.L., and Berardi, R.

Published
2022
Full Text
View/download PDF

6. In vitro cell culture of amniotic fluid keratinocytes on amniotic membrane: the ideal tissue for repairing skin ulcers

Author

Kiani, A K, Paolacci, S, Amato, B, Mattassi, R E, Tassi, V, Falsini, B, Di Renzo, G, Guda, T, Kallazi, M, Dautaj, A, Dhuli, K, Morrone, A, Bellinato, F, Gisondi, P, and Bertelli, M

Subjects
Adult, Keratinocytes, Reverse Transcriptase Polymerase Chain Reaction, Amniotic membrane, Wound healing, Amniotic Fluid, Pregnancy, Skin Ulcer, Humans, Tissue engineering, Female, Amnion, Amniotic stem cells, Cells, Cultured, Embryonic Stem Cells, Cell Proliferation
Abstract

The amniotic fluid contains a large population of stem keratinocytes demonstrating minimal immunological rejection. Recent evidence suggests that stem cells from the amniotic fluid can be employed in the field of tissue engineering. In this work we identified precursors of the epithelial cells and expanded them in vitro.After collecting samples of amniotic fluid and separating the cells via centrifugation, we seeded a portion of these cells in selection media to analyze the proliferation of epithelial cells. The stem cells precursors of keratinocytes were identified through specific markers. The expression of these markers was evaluated by immunofluorescence and reverse transcription polymerase chain reaction (PCR).The stem cells demonstrated 90% confluence, after undergoing proliferation in the selection medium for 15 days. Most of these cells tested positive for the keratinocyte-specific markers, but negative for stem cell specific markers. Of note, the identity of the keratinocytes was well established even after several subcultures.These results suggested that it is feasible to isolate and expand differentiated cell populations in the amniotic fluid from precursor cells. Furthermore, amniotic membranes can be utilized as scaffolds to grow keratinocytes, which can be potentially exploited in areas of skin ulcer transplantation and tissue engineering interventions.

Published
2021

8. Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study)

Author

Fiorelli, A., D'Andrilli, A., Carlucci, A., Vicidomini, G., Loizzi, D., Ardo, N. P., Marasco, R. D., Ventura, L., Ampollini, L., Carbognani, P., Bocchialini, G., Lococo, F., Paci, M., Di Stefano, T. S., Ardissone, F., Gagliasso, M., Mendogni, P., Rosso, L., Mazzucco, A., Vanni, C., Marinucci, B. T., Potenza, R., Matricardi, A., Ragusa, M., Tassi, V., Anile, M., Poggi, C., Serra, N., Sica, A., Nosotti, M., Sollitto, F., Venuta, F., Rendina, E. A., Puma, F., Santini, M., Lococo F. (ORCID:0000-0002-9383-5554), Fiorelli, A., D'Andrilli, A., Carlucci, A., Vicidomini, G., Loizzi, D., Ardo, N. P., Marasco, R. D., Ventura, L., Ampollini, L., Carbognani, P., Bocchialini, G., Lococo, F., Paci, M., Di Stefano, T. S., Ardissone, F., Gagliasso, M., Mendogni, P., Rosso, L., Mazzucco, A., Vanni, C., Marinucci, B. T., Potenza, R., Matricardi, A., Ragusa, M., Tassi, V., Anile, M., Poggi, C., Serra, N., Sica, A., Nosotti, M., Sollitto, F., Venuta, F., Rendina, E. A., Puma, F., Santini, M., and Lococo F. (ORCID:0000-0002-9383-5554)

Abstract

Background: Second cancer is the leading cause of death in lymphoma survivors, with lung cancer representing the most common solid tumor. Limited information exists about the treatment and prognosis of second lung cancer following lymphoma. Herein, we evaluated the outcome and prognostic factors of Lung Cancer in Lymphoma Survivors (the LuCiLyS study) to improve the patient selection for lung cancer treatment. Methods: This is a retrospective multicentre study including consecutive patients treated for lymphoma disease that subsequently developed non-small cell lung cancer (NSCLC). Data regarding lymphoma including age, symptoms, histology, disease stage, treatment received and lymphoma status at the time of lung cancer diagnosis, and data on lung carcinoma as age, smoking history, latency from lymphoma, symptoms, histology, disease stage, treatment received, and survival were evaluated to identify the significant prognostic factors for overall survival. Results: Our study population included 164 patients, 145 of which underwent lung cancer resection. The median overall survival was 63 (range, 58-85) months, and the 5-year survival rate 54%. At univariable analysis no-active lymphoma (HR: 2.19; P=0.0152); early lymphoma stage (HR: 1.95; P=0.01); adenocarcinoma histology (HR: 0.59; P=0.0421); early lung cancer stage (HR: 3.18; P<0.0001); incidental diagnosis of lung cancer (HR: 1.71; P<0.0001); and lung cancer resection (HR: 2.79; P<0.0001) were favorable prognostic factors. At multivariable analysis, no-active lymphoma (HR: 2.68; P=0.004); early lung cancer stage (HR: 2.37; P<0.0001); incidental diagnosis of lung cancer (HR: 2.00; P<0.0001); and lung cancer resection (HR: 2.07; P<0.0001) remained favorable prognostic factors. Patients with non-active lymphoma (n=146) versus those with active lymphoma (n=18) at lung cancer diagnosis presented better median survival (64 vs. 37 months; HR: 2.4; P=0.02), but median lung cancer specific survival showed

Published
2020

9. 126P Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Loreti, F., Italiani, M., Enrico, B., Fabiani, S., Marchetti, G., Tassi, V., Mancioli, F.A., Muti, M., Guida, A., Bracarda, S., Ragusa, M., Maranzano, E., and Trippa, F.

Published
2023
Full Text
View/download PDF

19. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

Author

Giani, T, Arena, F, Pollini, S, Di Pilato, V, D'Andrea, Mm, Henrici De Angelis, L, Bassetti, M, Rossolini, Gm, Vismara, C, Luzzaro, F, Cavallo, R, Dusi, Pa, Pagani, E, Sarti, M, Farina, C, Rigoli, R, Scarparo, C, Pecile, P, Cusi, Mg, Mencacci, A, Manso, E, Spanu, Teresa, Labonia, M, Tassi, V, Amato, G, Stefani, S, Giraldi, C, Rassu, M, Spanu T (ORCID:0000-0003-1864-5184), Giani, T, Arena, F, Pollini, S, Di Pilato, V, D'Andrea, Mm, Henrici De Angelis, L, Bassetti, M, Rossolini, Gm, Vismara, C, Luzzaro, F, Cavallo, R, Dusi, Pa, Pagani, E, Sarti, M, Farina, C, Rigoli, R, Scarparo, C, Pecile, P, Cusi, Mg, Mencacci, A, Manso, E, Spanu, Teresa, Labonia, M, Tassi, V, Amato, G, Stefani, S, Giraldi, C, Rassu, M, and Spanu T (ORCID:0000-0003-1864-5184)

Abstract

Objectives: Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/b-lactamase inhibitor combination with potent activity against P. aeruginosa. This survey was carried out to evaluate the susceptibility of P. aeruginosa, circulating in Italy, to ceftolozane/tazobactam and comparators and to investigate the molecular epidemiology of carbapenemase-producing strains. Methods: Consecutive non-replicate P. aeruginosa clinical isolates (935) from bloodstream infections and lower respiratory tract infections were collected from 20 centres distributed across Italy from September 2013 to November 2014. Antimicrobial susceptibility testing was performed by broth microdilution and results were interpreted according to the EUCAST breakpoints. Isolates resistant to ceftolozane/tazobactam were investigated for carbapenemase genes by PCR, and for carbapenemase activity by spectrophotometric assay. WGS using an Illumina platform was performed on carbapenemase-producing isolates. Results: Ceftolozane/tazobactam was the most active molecule, retaining activity against 90.9% of P. aeruginosa isolates, followed by amikacin (88.0% susceptibility) and colistin (84.7% susceptibility). Overall, 48 isolates (5.1%) were positive for carbapenemase genes, including blaVIM (n"32), blaIMP (n"12) and blaGES-5 (n"4), while the remaining ceftolozane/tazobactam-resistant isolates tested negative for carbapenemase production. Carbapenemase producers belonged to 10 different STs, with ST175 (n"12) and ST621 (n"11) being the most common lineages. Genome analysis revealed different trajectories of spread for the different carbapenemase genes. Conclusions: Ceftolozane/tazobactam exhibited potent in vitro activity against P. aeruginosa causing invasive infections in Italy. Carbapenemase production was the most common mechanism of resistance to ceftolozane/ tazobactam.

Published
2018

20. MA22.06 Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?

Author

Daddi, N., primary, Tassi, V., additional, Scarnecchia, E., additional, Allison, F., additional, Vannucci, J., additional, Capozzi, R., additional, Liparulo, V., additional, Yasufuku, K., additional, De Perrot, M., additional, Pierre, A., additional, Mete, Ö., additional, Colella, R., additional, Ascani, S., additional, Ferolla, P., additional, Darling, G., additional, Keshavjee, S., additional, Puma, F., additional, and Waddell, T.K., additional

Published
2018
Full Text
View/download PDF

22. CONGENITAL HYPOTHYROIDISM: A POPULATION BASED STUDY

Author

Tassi, V., Calaciura, F., Miscio, G., Majorana, A., Parrinello, G., Ranieri, A., Regalbuto, C., Sava, L., and Trischitta, V.

Subjects
Genetic research -- Analysis, Human genetics -- Research, Hyperthyroidism -- Genetic aspects, Biological sciences
Published
2000

23. Mapping a dominant form of multinodular goiter to chromosome Xp22

Author

Capon, F., Tacconelli, A., Sciacchitano, S., Bruno, R., Tassi, V., Trischitta, V., Filetti, S., Dallapiccola, B., and Novelli, G.

Subjects
Genetic research -- Analysis, Human genetics -- Research, Thyroid diseases -- Genetic aspects, Biological sciences
Published
2000

24. Rare Tumours of the Lung: A Single Centre Experience

Author

Pecoriello, R., Ceccarelli, S., Tassi, V., Capozzi, R., Vannucci, J., Daddi, N., Ragusa, M., Puma, F., Pecoriello R, Ceccarelli S, Tassi V, Capozzi R, Vannucci J, Daddi N, Ragusa M, and Puma F

Subjects
Lung cancer, RARE DISEASES
Abstract

Introduction: A rare tumour of the lung (RTL) is defined as neoplasm whose incidence is lower than 2% of all pulmonary tumours. Such group includes different benign and malignant lesions with variable occurrence rate. Aim of this study was to retrospectively analyze a single centre surgical experience and com- pare it with the literature. Patients and Methods: From February 2002 to April 2009 twenty-four patients underwent resection for RTL. Different procedures were utilized, including operative rigid bronchoscopy, wedge resection, lobectomy, pneumonectomy, and bronchoplastic procedures. All patients entered a follow-up program (median 22, range1-79 months). Results: According to the 2004 WHO classification 6 patients had benign (Group A) and 18 malignant (Group B) RTL. Group A: endobronchial hamartoma (n=1) endobronchial lipoma (n=1), endobronchial fibroepithelial polyp (n=1), benign fibrous hystiocitoma (n=1) and sclerosing hemangioma (n=2). Group B: pulmonary blastoma (B1, n=1), mucoepidermoid carcinoma (B2, n=1), adenoid cystic carcinoma (B3, n=3), inflammatory myofi- broblastic tumour (B4, n=1), pulmonary synovial sarcoma (B5, n=3), dendritic follicular cells sarcoma (B6, n=1), pleomorphic carcinoma (B7, n=2) spindle cell carcinoma (B8, n=2), and carcinosarcoma (B9, n=4). Symptoms were present mostly in centrally- located neoplasms (10/24, n=3 Group A and n=7 Group B). Two patients were lost at follow-up. Three patients with B9 died of the disease (median 14 months, range 4-15), one B8 immunocompromised patient had progressive disease after 3 months, the remaining are present alive without evidence of disease. Conclusions: Our results substantially reflect the literature data. A multicentre study would add to the knowledge of this heterogeneous group of tumours.

Published
2009

25. Update on Talc Pleurodesis. What’s New?

Author

Vannucci J, Capozzi R, Pecoriello R, Rao F, Floridi C, Bufalari A, Bravi I, Marziani F, Tassi V, Ceccarelli S, Ragusa M, Puma F., DADDI, NICCOLO', Vannucci J, Daddi N, Capozzi R, Pecoriello R, Rao F, Floridi C, Bufalari A, Bravi I, Marziani F, Tassi V, Ceccarelli S, Ragusa M, and Puma F.

Subjects
pleurodesis, TALC
Abstract

Introduction: Talc is currently the most common agent used for pleurodesis. Despite its role acknowledged as an effective bed side strategy primarily in neoplastic pleural effusion, recently it has been introduced in the treatment of benign diseases such as spontaneous pneumothorax. Aim of this study is to investigate side effects and results of different concentrations of talc pleurod- esis (TP) in rabbits. Materials and Methods: Twenty-six New Zealand rabbits were randomly injected intrapleurally with saline (n=6) or talc slurry at usual dosage 40mg/kg (T40, n=10) and 200mg/kg (T200, n=10). Chest tube was opened at day1 post-operative and removed in day4. Clinical signs and symptoms, fluid lactate dehydrogenase and protein levels were measured daily after the injection until drainage removal, then on day7 and before sacrifice. All groups were equally divided in two endpoints: day14 and day28. At post- mortem examination, pleurodesis was graded, according to Light criteria, from 1(none) to 8(>50% symphysis), by two observers blinded to treatment groups. Results: Adverse reactions were discovered with fever and weight loss in T200 group at 14 and 28 days. Pleurodesis score in the control Saline was negative while it did not differ significantly between T200 (4.0±1.4 at 14 days, 4.2±1.6 at 28 days) and T40 (2.8±2.0 at 14 days, 3.6±1.9 at 28 days) at days 14 and 28 (p=0.25 and p=0.56 respectively). Microscopically several granulomas, moderate localized pleural thickness, few areas of neoangiogen- esis and mediastinal lymphathic tissue infiltration were present in both study groups. Conclusions: TP at usual clinical dosage is well tolerated with acceptable clinical results. By increasing the concentration we observed severe side-effects with only mild improvement of pleurodesis.

Published
2009

26. Surgical Treatment of Non Malignant Tracheal Lesions: A Single Center Experience

Author

DADDI, NICCOLO', Urbani M, Semeraro A, Lomonaco A, Capozzi R, Pecoriello R, Tassi V, Sciamannini M, Puma F, Daddi G., Daddi N, Urbani M, Semeraro A, Lomonaco A, Capozzi R, Roberta P, Tassi V, Sciamannini M, Puma F, Daddi G, and Pecoriello R

Subjects
TRACHEA, BENIGN, stenosis, respiratory system
Abstract

Introduction: Different etiologies are responsible for a wide spectrum of tracheal injuries. Some of these, such as cicatricial laryngo-tracheal stenosis and tracheoesophageal fistula (T-E) not rarely represent a challenge in tracheal surgery. Aim of this study is to retrospectively review the pattern of post-intubation lesions, extension of surgery and long term results in 49 patients. Methods: From December 1987 to February 2007, 49 patients (23 males and 26 females), mean age 50 (range 15–78), were submit- ted to surgical treatment: cicatricial tracheal stenosis (Group A), T-E fistula (Group B), and tracheal tear (Group C). All patients were symptomatic. Results: No post-operative deaths. In Group A (n = 34) the stricture was considered moderate (residual lumen:30–50%) in 27 patients, and severe (

Published
2007

27. A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria

Author

De Cosmo, S, Argiolas, A, Miscio, G, Thomas, S, Piras, G, Trevisan, R, Perin, P, Bacci, S, Zucaro, L, Margaglione, M, Frittitta, L, Pizzuti, A, Tassi, V, Viberti, G, Trischitta, V, De Cosmo S, Argiolas A, Miscio G, Thomas S, Piras GP, Trevisan R, Perin PC, Bacci S, Zucaro L, Margaglione M, Frittitta L, Pizzuti A, Tassi V, Viberti GC, Trischitta V, De Cosmo, S, Argiolas, A, Miscio, G, Thomas, S, Piras, G, Trevisan, R, Perin, P, Bacci, S, Zucaro, L, Margaglione, M, Frittitta, L, Pizzuti, A, Tassi, V, Viberti, G, Trischitta, V, De Cosmo S, Argiolas A, Miscio G, Thomas S, Piras GP, Trevisan R, Perin PC, Bacci S, Zucaro L, Margaglione M, Frittitta L, Pizzuti A, Tassi V, Viberti GC, and Trischitta V

Abstract

Insulin resistance characterizes type I diabetes in patients with albuminuria. A PC-1 glycoprotein amino acid variant, K121Q, is associated with insulin resistance. We examined the impact of the PC-1 K121Q variant on the rate of decline of the glomerular filtration rate (GFR) by creatinine clearance derived from the Cockroft-Gault formula in 77 type I diabetic patients with albuminuria who were followed for an average of 6.5 years (range 2.5-15). Patients carrying the Q allele (n = 22; 20 with KQ and 2 with QQ genotypes) had a faster GFR decline than those patients with the KK genotype (n = 55) (median 7.2 vs. 3.7 ml · min-1 · year-1; range 0.16 to 16.6 vs. -3.8 to 16.0 ml · min-1 · year-1; P< 0.001). Significantly more patients carrying the Q allele belonged to the highest tertile of GFR decline (odds ratio = 5.7, 95% CI 4.1-7.2, P = 0.02). Levels of blood pressure, HbA(1c), and albuminuria were comparable in the two genotype groups. Albuminuria (P = 0.001), mean blood pressure (P = 0.046), and PC-1 genotype (P = 0.036) independently correlated with GFR decline. Because all patients were receiving antihypertensive treatment, the faster GFR decline in the patients carrying the Q allele could be the result of reduced sensitivity to the renoprotective effect of antihypertensive therapy. PC-1 genotyping identifies type I diabetic patients with a faster progression of diabetic nephropathy.

Published
2000

33. Screening of thyrotropin receptor mutations by fine-needle aspiration biopsy in autonomous functioning thyroid nodules in multinodular goiters

Author

Tassi, V., DI CERBO, A., Porcellini, A., Papini, E., Cisternino, C., Crescenzi, A., Scillitani, A., Pizzuti, Antonio, Ratti, A., Trischitta, Vincenzo, Avvedimento, V. E., DE FILIPPIS, G. FENZI V., Tassi, V, DI CERBO, A, Porcellini, Antonio, Papini, E, Cisternino, C, Crescenzi, A, Scillitani, A, Pizzuti, A, Ratti, A, Trischitta, V, Avvedimento, Ve, and Fenzi, G.

Published
1999

36. PAX8 mutations associated with congenital hypothyroidism caused by thyroid

Author

MACCHIA, PAOLO EMIDIO, MISSERO, Caterina, FENZI, GIANFRANCO, DI LAURO, ROBERTO, Lapi P, Krude H, Pirro MT, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Grüters A, Busslinger M, Macchia, PAOLO EMIDIO, Lapi, P, Krude, H, Pirro, Mt, Missero, Caterina, Chiovato, L, Souabni, A, Baserga, M, Tassi, V, Pinchera, A, Fenzi, Gianfranco, Grüters, A, Busslinger, M, and DI LAURO, Roberto

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results